Pricing Log in Create free account
Saturday 17 October 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024. In the quarter to June 2026, revenue grew 55.4%, EPS grew 37.5% and free cash flow grew 66.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for five.

78.59 1.35 −1.69%
Market cap
$6.2B
P/E
73.4×
Fwd P/E
38.7×
Dividend yield
—
F-score
8/9
Altman Z
10.35
Beneish M
−3.16
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Kiniksa Pharmaceuticals International, plc (KNSA) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a P/E ratio of 73.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 646× (September 2025); the current reading is higher than 87% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and above the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 51.6× —
FY2024 0.0× —
FY2023 97.5× 1,683.03%
FY2022 5.5× —
FY2021 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 59.8× 21.64%
Mar 2026 49.1× (4.71%)
Dec 2025 51.6× (34.93%)
Sep 2025 79.2× (82.82%)
17 more quarters

Against its own ten years

Low 0.0× High 646×
Ten-year median 0.0×
Current reading's percentile 87

P/E ratio against peers

Company P/E ratio
AMLX Amylyx Pharmaceuticals, Inc. compare n/m
HIMS Hims & Hers Health, Inc. compare n/m
RGC Regencell Bioscience Holdings Limited compare n/m
INDV Indivior Pharmaceuticals Inc. compare 11.2×
LNTH Lantheus Holdings, Inc. compare 23.7×
RDY Dr. Reddy's Laboratories Ltd compare 32.9×
AMRX AMNEAL PHARMACEUTICALS, INC. compare 38.4×
KNSA Kiniksa Pharmaceuticals International, plc 73.4×
ALKS Alkermes plc compare 102×
Drug Manufacturers Specialty & Generic industry median 19.2×
Healthcare sector median 23.0×
Market median 18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on KNSA